As a mid-sized global biopharmaceutical company, Ipsen improves patients’ lives through research, innovation and the development of transformative medicines in Oncology, Rare Disease and Neuroscience.


Improving people’s lives and health outcomes by focusing on areas of high unmet medical need, we are accelerating our momentum and rapidly boosting our pipeline to bring the full potential of our innovative medicines to patients.

Author Image

Our strategy has been instrumental in making us a leader in our field. Our global presence, resources, expertise and strong track record commercializing our medicines are resulting in a real impact for people living with high unmet medical needs. We’re leveraging the full force of Ipsen’s infrastructure, innovation and passion to develop new therapies and valuable collaborations.

The latest highlights from Ipsen

Find out what’s been going on at Ipsen of late – with press releases, trending stories, events, and more.


Putting patients at the heart of our work

Our commitment to improving the lives and medical outcomes of patients is the driving force behind every decision made at Ipsen. We believe in working with patients, for patients, listening to their needs and involving their insights in the entire….


Shaping a more sustainable future

Ipsen is dedicated to safeguarding and preserving our planet. The Generation Ipsen ESG responsibility strategy lays out ambitious goals for the company in each of four pillars: Environment, Patients, People and Governance.

Careers at Ipsen

Ipsen offers a multitude of exciting opportunities for talented and motivated people in careers ranging from medial and clinical research to sales, marketing, finance, IT, HR and legal services. We are committed to providing our employees with a workplace that is welcoming, challenging and inclusive.

Top Ipsen stories

02 June 2023 1 mins read
Ipsen’s partnership with Marengo

Find out more about how we approach partnerships at Ipsen, where every program is a priority within our pipeline. We sat down with Zhen Su, CEO Marengo, to discuss our partnership and how we undertake a one team approach to accelerate innovation for the pa

01 June 2023 1 mins read
Ipsen’s 2022 Integrated Annual Report now available

2022 was a year of focus, momentum and growth at Ipsen. Learn about the progress we made and download the 2022 Integrated Annual Report here.

23 May 2023 1 mins read
Fireside Chat: Innovation and Policy Change in Rare Diseases

The rare disease community continues to strive for innovative solutions to meet patient needs and ensure no person living with a rare disease is left behind.  

12 May 2023 4 mins read
Understanding the true impact of living with FOP

This year marks the 17th anniversary since the discovery of the ACVR1 gene was announced, a major scientific milestone in fibrodysplasia ossificans progressiva (FOP) research that helped us understand what causes the condition. On April 23,

23 May 2023 2 mins read
Applications now open for the 2023 Golden Ticket Competition

As part of our commitment to accelerating transformative research and development, we’re excited to announce that our Golden Ticket Competition is now open! Through our continued partnership with Biolabs, we’re delighted to be offering the brightest mi

09 February 2023 1 mins read
Ipsen FY/Q4 2022 results–A word from CEO David Loew

Hear what Ipsen CEO David Loew has to say about our strong full year and Q4 2022 results.

05 January 2023 2 mins read
J.P. Morgan Conference 2023: Ipsen shares strategy success

Ipsen leaders will attend the J.P. Morgan Healthcare Conference from January 9-12, 2023, in San Francisco, California. This event will bring together biotech companies, clinical researchers, investors and analysts from all over the world to learn about hea

20 December 2022 1 mins read
Living with PBC: The Person Behind the Chart

‘Invisible’ diseases like primary biliary cholangitis (PBC) can be difficult to recognise, diagnose and to manage effectively. Here Prof. Gideon Hirschfield (University of Toronto, Departments of Medicine, Immunology and Medical Sciences) and Robert Mi